PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair folliclestemcells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
A method for treating androgenic alopecia using minoxidil, antiandrogens, exercise, and cold exposure to promote hair growth. Environmental factors and lifestyle changes, like diet and exercise, can improve treatment effectiveness.
Treating androgenic alopecia with minoxidil, finasteride, and antiandrogens, alongside exercise, cryotherapy, and natural substances to stimulate cold receptors for better hair growth. The method focuses on enhancing treatment effectiveness by considering environmental and behavioral factors and the role of cold receptors and muscle stress.
A user is organizing a group buy for various compounds aimed at reversing hair loss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
The conversation discusses the potential of long-chain unsaturated fatty acids, like oleic and linoleic acid, as an additional treatment for hair loss, which may inhibit the enzyme responsible for converting testosterone to DHT and promote hair growth. Users humorously suggest using oils topically and discuss other hair loss treatments, but the main focus is on the science behind fatty acids and their role in hair health.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
A new study that found a single chemical could potentially be responsible for hair loss, and the potential to use this discovery to stimulate hair growth. The conversation also includes various treatments such as Minoxidil, Finasteride, RU58841, microneedling, DUT, and Botox for hair loss.
Male androgenetic alopecia is commonly treated with topical minoxidil and oral finasteride, both requiring continuous use. Other options include hair restoration surgery, dutasteride, light therapy, and camouflaging agents.
The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.
Hair follicle cloning is claimed to be possible but not widely available due to potential safety issues, such as cancer risks. Current treatments like finasteride and dutasteride are not effective for everyone, and there is frustration over limited access to these medications.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
A new technique developed by scientists in Japan to reverse balding using hair follicle cell transplants, and the discussion around the effectiveness of this approach compared to other treatments such as Minoxidil, finasteride, RU58841, Replicel, and Hairclone.
There have been no new effective hair loss treatments since finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.
A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.
New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.
The conversation discusses the confusion over low testosterone potentially causing hair loss, with users sharing personal experiences and knowledge about hair loss treatments like Finasteride. Some users suggest that hair follicle sensitivity to DHT, not testosterone levels, is the key factor in balding, and others discuss the side effects of hair loss medications.
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.
CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
The conversation discusses the complexity of hair loss causes, suggesting that DHT sensitivity alone doesn't fully explain it. Treatments mentioned include finasteride and dutasteride.
The method combines finasteride, minoxidil, intense leg exercises, and cold exposure to treat androgenetic alopecia. It aims to boost metabolism and reduce androgenic effects, enhancing hair growth.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
Researching the effects of scalp trauma on hair growth, with some users suggesting experimenting with a soldering iron or derma pen, and others bringing up studies that suggest this may be an effective treatment.
Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.
